Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Laboratories Ltd (NYSE:RDY) reported Tuesday a second-quarter 2025 net income of $160 million, down from $177 million a year ago.
德拉迪實驗室有限公司 (紐交所:RDY) 週二報告2025年第二季度的凈利潤爲16000萬，低於去年的17700萬。
Revenue increased from $821 million to $957 million — almost a 16.6% jump.
營業收入從82100萬增長到95700萬，幾乎增長了16.6%。
The strong revenue growth during the quarter was primarily driven by growth in global generics revenues. The sequential growth was led by global generics revenues in Emerging Markets, India, Europe and Pharmaceutical Services and Active Ingredients (PSAI).
季度內的強勁營業收入增長主要得益於全球仿製藥收入的增長。順序增長主要來自新興市場、印度、歐洲以及藥品服務和活性成分（PSAI）的全球仿製藥收入。
EBITDA for the quarter rose from $260 million to $272 million.
本季度的EBITDA從26000萬上升至27200萬。
"We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands," said co-chair GV Prasad.
"我們又交出了一個不錯的季度，並維持了各業務的增長勢頭。我們在未來的增長驅動因素上取得了進展，將與雀巢的創業公司落地，並完成了對尼科汀和相關品牌的收購，" 聯合主席GV Prasad表示。
Global generics revenues during the second quarter reached 71.6 billion rupees, showing a 17% year-over-year growth, driven by improved sales volumes and new product launches.
第二季度全球仿製藥收入達到716億盧比，同比增長17%，這主要得益於銷售量的提升以及新產品的推出。
North American sales increased 17% (a sequential decline of 3%) to 37.3 billion rupees. YoY growth was largely due to increased sales volumes, partly offset by price erosion. The sequential decline was due to a decrease in sales volumes.
北美銷售額增長了17%（環比下降3%）至373億盧比。同比增長主要是由於銷售量增加，部分被價格侵蝕所抵消。環比下降是由於銷售量減少。
Gross Margin at 59.6% (GG: 63.1 %, PSAI: 30.0%), a YoY increase of 92 basis points (bps) and a QoQ decline of 81 bps. The YoY increase was due to an improvement in product mix and overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily due to changes in the mix.
毛利率爲59.6%（GG: 63.1%，PSAI: 30.0%），同比增長92個點子（bps），環比下降81個點子。同比增長是由於產品組合改善和間接費用槓桿，部分被價格侵蝕抵消。按順序來看，下降主要是由於組合的變化。
Price Action: Dr. Reddy's Laboratories is up 4.81% at $15.51 during the premarket session at last check Tuesday.
價格走勢：截至週二盤前檢查，Dr. Reddy's Laboratories股價上漲4.81%，達15.51美元。
- Short Squeeze – GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook
- 做空擠壓 – GlobalFoundries股票因第三季度業績超過預期和強勁的第四季度展望而飆升。
